Long-term cardiometabolic effects of early institutionalization and foster care: Evidence from the Bucharest Early Intervention Project.

Dev PsychopatholMay 15, 2026 (epub)
Clinical ResearchCardiologyEndocrinologyOpen access

Michelle M J Mens, Ellen Jopling, Megan Hare et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the long-term cardiometabolic effects of early institutionalization and foster care in 139 young adults (mean age 22.6 years) from the Bucharest Early Intervention Project. Results showed that individuals with a history of institutionalization had poorer lipid metabolism, and those randomized to foster care exhibited higher BMI and waist circumference compared to those in institutional care, indicating ongoing cardiometabolic risks.

Key findings

  • Adults with histories of institutionalization had poorer lipid metabolism compared to non-institutionalized controls.
  • Foster care participants had increased BMI and waist circumference relative to those in institutional care.
  • An accelerated BMI trajectory was linked to the highest prevalence of metabolic syndrome among foster care participants.

Why it matters

Understanding the long-term cardiometabolic risks associated with early institutionalization and foster care is crucial for developing targeted monitoring and intervention strategies for affected individuals, potentially improving their health outcomes.

Source

Published in Dev Psychopathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.